

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Masayoshi Shichiri et al.	Confirmation	5652
Serial No.:	10/518,870	Group Art	1614
Filed:	August 29, 2005	Examiner:	Pagonakis, Anna
For:	NOVEL USE OF ANSAMYCIN ANTIBIOTICS AND METHOD OF SCREENING NOVEL ANGIOGENESIS INHIBITOR		

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the Restriction Requirement dated June 27, 2008 in which claims 1-23 were subjected to restriction. The applicants elect to prosecute Group II (*i.e.*, claims 1-8 and 12-22 drawn to an angiogenesis inhibitor containing an ansamycin antibiotic or a pharmacologically acceptable derivative thereof as an active ingredient). With respect to the species election, the applicants elect rifampicin as the form of ansamycin antibiotic, and a malignant tumor species as the form of angiogenesis. Entry and consideration of the amendment is respectfully requested.

Under 37 C.F.R. §1.7(a) when the last day to take action falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, the action may be taken on the next succeeding business day which is not a Saturday, Sunday, or Federal holiday, *i.e.*, July 28, 2008 without additional extension fees.

Amendments to the Claims are reflected on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.